Brii Bio acquires Vir’s antibody rights for Hepatitis B in Greater China
The development adds further growth to Brii Bio’s clinical pipeline of therapeutic candidates for HBV.
Deal News
Latest in
Deal News
GSK acquires US-based Sierra Oncology for $1.9bn
In June this year, Sierra filed a New Drug Application with the US Food and Drug Administration for momelotinib.
Oxford Biomedica, AstraZeneca enter new deal for Covid-19 vaccine
According to the new deal, AstraZeneca will have access to Covid-19 vaccine manufacturing at Oxford Biomedica’s Oxbox facility.
Blueprint Medicines announces financing partnerships for $1.25bn
At the closing of the deal, Blueprint will get a total of $575m in cash.
Twist and Ildong to develop antibodies for immuno-oncology applications
Under the deal, Twist will receive upfront, milestone and royalty payments as well as annual maintenance fees.
Eczacıbaşı to acquire Turkish pharma company Gensenta for $135m
Following the acquisition, Amgen Turkey will maintain its operations and serve its patients in the region.
Terumo and GenCure sign agreement for cell and gene therapies
The alliance will use Terumo and GenCure’s capabilities to set up a reference manufacturing centre for BioBridge Global.
Astellas and Sutro partner to develop immunostimulatory ADCs
Sutro could be eligible for milestone payments of up to $422.5m for each product candidate.